We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Terlipressin in Septic Shock: Effects on Microcirculation

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00995839
First Posted: October 15, 2009
Last Update Posted: February 4, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University of Roma La Sapienza
  Purpose
The present study was conducted as a prospective, randomized study to investigate the effects of vasopressin receptor agonists terlipressin and vasopressin on systemic hemodynamics and microcirculation in patients with catecholamine-dependent septic shock.

Condition Intervention Phase
Septic Shock Sepsis Drug: continuous infusion of terlipressin Drug: Arginine vasopressin Drug: terlipressin bolus administration Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Vasopressin Receptor Agonists in Septic Shock: Effects on Microcirculation

Resource links provided by NLM:


Further study details as provided by University of Roma La Sapienza:

Primary Outcome Measures:
  • Systemic hemodynamic and Microcirculatory flow index of small and medium vessels (MFI) [ Time Frame: over a period of 6 hrs from the time of randomization ]
  • Oxygen transport variables [ Time Frame: over a period of 6 from the time of randomization ]

Secondary Outcome Measures:
  • Acid-base homeostasis [ Time Frame: over a period of 6 hrs from the time of randomization ]
  • Functional capillary density (mm/mm2) (FCD) [ Time Frame: over a period of 6 hrs from the time of randomization ]
  • De Backer score [ Time Frame: over a period of 6 hrs from the time of randomization ]
  • Perfused Vessel Density (PVD) (mm/mm2) [ Time Frame: over a period of 6 hrs from the time of randomization ]
  • Proportion of Perfused vessels (%) (PPV) [ Time Frame: over a period of 6 hrs from the time of randomization ]

Enrollment: 60
Study Start Date: November 2008
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: continuous terlipressin Drug: continuous infusion of terlipressin
Intravenous continuous infusion of terlipressin 1 µg•kg-1•h-1 for 6 hrs
Experimental: vasopressin Drug: Arginine vasopressin
Intravenous continuous infusion of arginine vasopressin 0.04 UI•min-1 for 6 hrs
Experimental: terlipressin bolus dose Drug: terlipressin bolus administration
intravenous terlipressin bolus administration at the dose of 0.5 mg

Detailed Description:

60 septic shock patients requiring norepinephrine to maintain mean arterial pressure between 65 and 75 mmHg despite adequate volume resuscitation will be enrolled in the study. After an initial hemodynamic resuscitation aimed at achieve a mean arterial pressure between 65 and 75 mmHg and normovolemia, patients will be randomly allocated to be treated with either a) intravenous administration of terlipressin 1 µg∙kg-1∙h-1 for 6 hrs, b) intravenous administration of arginine vasopressin 0.04 UI∙min-1 for 6 hrs, c) intravenous administration of terlipressin bolus dose of 0.5 mg (each n = 20). In all groups open label norepinephrine will be additionally administered to maintain a mean arterial pressure (MAP) between 65 and 75 mmHg, if necessary. Data from right heart catheterization and sublingual microvascular network will be obtained just before randomization (baseline) and then after 6 hours in the vasopressin, terlipressin infusion and terlipressin bolus groups.

The sublingual microvascular network will be studied using the sidestream dark field (SDF)imaging. The device will be applied on the lateral side of the tongue, in an area approximately 2-4 cm from the tip of the tongue. Sequences of 10 secs from eight adjacent areas will be recorded on disk using a personal computer. These sequences will be later analyzed by an investigator blinded to the patient's diagnosis and therapy.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of septic shock
  • Vasopressor support to maintain mean arterial pressure (MAP) between 65 and 75 mmHg despite adequate volume resuscitation (pulmonary artery occlusion pressure = 13-18 mmHg and central venous pressure = 8-12 mmHg)

Exclusion Criteria:

  • Pregnancy
  • Age < 18 years
  • Present or suspected acute mesenteric ischemia
  • Vasospastic diathesis (e.g. Raynaud's syndrome or related diseases)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00995839


Locations
Italy
Departement of Anesthesiology and Intensive Care
Rome, I, Italy, 00161
Sponsors and Collaborators
University of Roma La Sapienza
Investigators
Principal Investigator: Andrea Morelli, MD University of Rome "La Sapienza", Department of Anesthesiology and Intensive Care
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Andrea Morelli, University of Rome "La Sapienza"
ClinicalTrials.gov Identifier: NCT00995839     History of Changes
Other Study ID Numbers: 1065
First Submitted: October 14, 2009
First Posted: October 15, 2009
Last Update Posted: February 4, 2010
Last Verified: October 2009

Keywords provided by University of Roma La Sapienza:
terlipressin
vasopressin
sepsis
septic shock
norepinephrine

Additional relevant MeSH terms:
Sepsis
Shock
Shock, Septic
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Vasopressins
Arginine Vasopressin
Lypressin
Terlipressin
Hemostatics
Coagulants
Vasoconstrictor Agents
Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs
Antihypertensive Agents